Meet the latest winners of Venture Kick’ stage two
07.07.2015
The ETH and PSI spin-off InterAx Biotech, and the EPFL spin-off ObViz, just won the second stage of Venture Kick and its CHF 20’000 of pre-seed capital. With them, innovative systems for drug discovery and a novel tool to read, exchange and balance opinions on the Internet are on their way to serve a large number of people in the future.
 The team of ObViz
|
 |
 Meet InterAx Biotech
|
|
Taking decisions on controversial issues? More obvious with ObViz
After winning two great awards in May this year, Lausanne based startup ObViz is now preparing for the big Venture Kick final together with InterAx Biotech from Zurich.
Controversial topics always have pro and con opinions, especially on the web. People often lack knowledge to exchange, balance or take a decision. The opinion-based and vizualisation platform ObViz helps people in this process, thus exploring and understanding controversies. It addresses the lack of structured information on the internet on controversial subjects using cutting edge artificial intelligence.
Just as the Press for More Award described on their website: "If you need to make a decision, like vaccinating your child or not, the outcome will be very different depending on what article you happen to read first. Most people don't have an expert that they can just ask, so they need trustworthy information. And that is exactly the role which obviz.com has taken up."
InterAx Biotech: Helping pharmaceutical companies to develop better drugs
Over one third of all marketed drugs target G protein-coupled receptors. Dissection of drug-induced signaling requires understanding and access to complexes composed of receptor and signaling protein. These complexes are transient and dynamic in nature. InterAx Biotech, a spin-off of ETH Zurich and Paul Scherrer Institute, provides stabilized complexes for drug discovery. Their products are the missing tools necessary for comprehensive drug-induced signaling analysis contributing to qualified decisions before entering clinical trials.
After winning two great awards in May this year, Lausanne based startup ObViz is now preparing for the big Venture Kick final together with InterAx Biotech from Zurich.
Controversial topics always have pro and con opinions, especially on the web. People often lack knowledge to exchange, balance or take a decision. The opinion-based and vizualisation platform ObViz helps people in this process, thus exploring and understanding controversies. It addresses the lack of structured information on the internet on controversial subjects using cutting edge artificial intelligence.
Just as the Press for More Award described on their website: "If you need to make a decision, like vaccinating your child or not, the outcome will be very different depending on what article you happen to read first. Most people don't have an expert that they can just ask, so they need trustworthy information. And that is exactly the role which obviz.com has taken up."
InterAx Biotech: Helping pharmaceutical companies to develop better drugs
Over one third of all marketed drugs target G protein-coupled receptors. Dissection of drug-induced signaling requires understanding and access to complexes composed of receptor and signaling protein. These complexes are transient and dynamic in nature. InterAx Biotech, a spin-off of ETH Zurich and Paul Scherrer Institute, provides stabilized complexes for drug discovery. Their products are the missing tools necessary for comprehensive drug-induced signaling analysis contributing to qualified decisions before entering clinical trials.